Jupiter Life Line Hospitals Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Jupiter Life Line Hospitals Ltd filed with BSE on 07 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Jupiter Life Line Hospitals reported total income of INR411 crores for Q1 FY27 with EBITDA of INR79.3 crores at a 19.3% margin and PAT of INR37.5 crores. Management said Dombivli Hospital completed its first full quarter of operations, contributing a INR9.5 crores drag on EBITDA, broadly in line with expectations. Management also discussed occupancy trends across Thane, Pune, Indore and Dombivli, an acquisition to set up an IV fluids manufacturing unit, and clarified queries on pledged shares and debt levels.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Total income: INR411 crores (Q1 FY27)
p. 3
“Total income for the quarter stood at INR411 crores in Q1 of FY '27.”
Ankit Thakker, page 3 of the filed PDF · View the filing
EBITDA: INR79.3 crores, 19.3% margin (Q1 FY27)
p. 3
“The EBITDA stood at INR79.3 crores and with a margin of 19.3%.”
Ankit Thakker, page 3 of the filed PDF · View the filing
PAT: INR37.5 crores (Q1 FY27)
p. 3
“The PAT was INR37.5 crores.”
Ankit Thakker, page 3 of the filed PDF · View the filing
ARPOB: INR73,500 (Q1 FY27)
p. 3
“The ARPOB for the quarter is INR73,500 and the ALOS is 3.76 days.”
Ankit Thakker, page 3 of the filed PDF · View the filing
Average occupancy rate: 59.6% (Q1 FY27)
p. 3
“The average occupancy rate stood at 59.6% this quarter, considering the dilution on account of the expanded base of Dombivli beds.”
Ankit Thakker, page 3 of the filed PDF · View the filing
Dombivli EBITDA drag: INR9.5 crores (Q1 FY27)
p. 3
“This quarter has contributed to a INR9.5 crores drag on the EBITDA, pretty much in line with anticipation.”
Ankit Thakker, page 3 of the filed PDF · View the filing
Dombivli occupancy: 25%, 30% (Q1 FY27)
p. 6
“So occupancy should be around 25%, 30%, I think.”
Ankit Thakker, page 6 of the filed PDF · View the filing
Current debt and cash: roughly INR500 crores of debt with INR500 crores of cash
p. 8
“Currently, we are at pretty much 0 net debt. I don't have the exact number, but roughly INR500 crores of debt with INR500 crores of cash.”
Ankit Thakker, page 8 of the filed PDF · View the filing
IV fluids unit cost: INR35 crores, INR40 crores with infra
p. 6
“the one line of IV fluids cost INR35 crores, INR40 crores with the infra.”
Ankit Thakker, page 6 of the filed PDF · View the filing
Dombivli fixed cost: INR6 crores, INR7 crores per month
p. 4
“Fixed cost, I think, should be INR6 crores, INR7 crores for a month currently.”
Ankit Thakker, page 4 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Dombivli EBITDA breakeven timeline — breakeven · 1.5 to 2 years
stated firmly by Ankit Thakker
p. 6
“No, the guidance still holds.”
Ankit Thakker, page 6 of the filed PDF · View the filing
Board debt ceiling — 3x of EBITDA
stated firmly by Ankit Thakker
p. 8
“Currently, the board-imposed ceiling is debt of 3x of EBITDA, but we think that we should be able to complete the current round well within that range.”
Ankit Thakker, page 8 of the filed PDF · View the filing
Hospital project delivery — all 3 announced projects delivered · 5 years
stated as an aspiration by Ankit Thakker
p. 8
“currently, I only have a 5-year visibility, which is we would like to see that all 3 projects that we have announced should be delivered in these 5 years.”
Ankit Thakker, page 8 of the filed PDF · View the filing
Oncology launch at Dombivli — radiation and LINAC operational · end of the year
stated firmly by Ankit Thakker
p. 9
“Oncology is yet to be fully launched, the radiation and LINAC, etcetera, should come in by end of the year.”
Ankit Thakker, page 9 of the filed PDF · View the filing
ARPOB growth for mature units — inflation-linked growth
stated as an aspiration by Ankit Thakker
p. 5
“So broadly inflation-linked growth for the mature units and for the new units, inflation with -- higher than inflation because case mix keeps improving for a few years.”
Ankit Thakker, page 5 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Higher costs due to new team buildup and doctor hires ahead of next expansion phase.
Answered by Ankit Thakker
Asked by Dhvani Shah: Why did Indore EBITDA margin come in lower this quarter despite revenue growth?
p. 3
“So Indore, as I said, we are getting ready for the next phase of expansion. We have had some new team buildup, new doctor hires, etcetera.”
Ankit Thakker, page 3 of the filed PDF · View the filing
Guidance is based only on currently operating beds.
Answered by Ankit Thakker
Asked by Palkesh Jain: Does the EBITDA loss guidance factor in the new 300 beds coming online?
p. 4
“It is based on the currently operating beds.”
Ankit Thakker, page 4 of the filed PDF · View the filing
Ramp-up model shows losses only in the initial 1-2 years, then fluctuating margins but no further losses.
Answered by Ankit Thakker
Asked by Palkesh Jain: Will EBITDA loss increase temporarily as new beds become operational?
p. 5
“So operational EBITDA drag or losses are only anticipated in the initial 1 or 2 years of operations.”
Ankit Thakker, page 5 of the filed PDF · View the filing
Combination of case mix improvement and insurance contract renegotiations.
Answered by Ankit Thakker
Asked by Dikshant Gupta: What explains the 10% ARPOB growth this quarter?
p. 5
“So 2 main factors of ARPOB growth are case mix improvement and contract renegotiations with insurance companies or pricing, which happen on an ongoing basis.”
Ankit Thakker, page 5 of the filed PDF · View the filing
Management prefers to wait for more quarters of data before revising guidance.
Answered by Ankit Thakker
Asked by Abdulkader Puranwala: Why is management holding on to Dombivli guidance despite a strong start?
p. 7
“Currently, I don't think we want to be very adventurous and aggressive in guidance.”
Ankit Thakker, page 7 of the filed PDF · View the filing
The pledge amount is unchanged; the apparent increase was due to erroneous reporting after a share split, since corrected.
Answered by Ankit Thakker
Asked by Janardan Sharma: Why have shares pledged in favor of Catalyst Trusteeship increased materially?
p. 8
“So this is a non-promoter pledge by somebody else, which was erroneously reported as being magnified due to the split, but it is what it was earlier.”
Ankit Thakker, page 8 of the filed PDF · View the filing
Currently mostly self-paid patients; empanelment should reduce friction and help occupancy once complete.
Answered by Ankit Thakker
Asked by Raj Mehta: What is the current payer mix at Dombivli and expected occupancy improvement post insurance empanelment?
p. 9
“So currently, when in the initial phases, it's pretty much all self-paid patients with a little bit of -- the insurance comes in with 2 ways, a little bit of reimbursement-based insurance and a little bit of preauthorized case-to-case based insurance.”
Ankit Thakker, page 9 of the filed PDF · View the filing
It is a backward integration for the pharmacy subsidiary and a cost/margin improvement strategy, not entry into pharma manufacturing as a core business.
Answered by Ankit Thakker
Asked by Amey Chalke: What is the strategic rationale for acquiring a company to set up an IV fluids unit?
p. 7
“So what I want to tell you and everybody else is that this is not our entry into becoming a pharma company. We continue to remain a hospital company, but this is to be seen as a backward integration of our pharmacy subsidiary.”
Ankit Thakker, page 7 of the filed PDF · View the filing
Risks flagged
Dombivli ramp-up dependent on insurance empanelment friction
p. 9
“Reimbursement is seen as a cumbersome process for the patients. And as soon as the friction point of reimbursement goes away and cashless empanelment comes in, it should definitely result in some kind of occupancy.”
Ankit Thakker, page 9 of the filed PDF · View the filing
Rising fixed costs at Dombivli due to continued doctor hiring
p. 6
“So, on that account, the fixed cost can increase a little bit over the next year or 2.”
Ankit Thakker, page 6 of the filed PDF · View the filing
Pune growth plateauing due to occupancy nearing ceiling
p. 7
“So the growth will not stagnant, but it will plateau from here onwards or slow down from here onwards in terms of percentage, unlike in the earlier phases where you see a more sharper growth.”
Ankit Thakker, page 7 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.